Cite

    Crothers, J. et al. (2022). Corrigendum to "Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized active-controlled trial" [Vaccine 40(19) (2022) 2705–2713]. Vaccine. 40 (25), pp. 3481-. [Online].